Therapie der Endometriose

In: Gynäkologie und Geburtshilfe 1988 · 1989 · pp. 937–940 · doi:10.1007/978-3-642-74784-7_482 · W2412349714
book-chapter OA: closed CC0 ⤵ 5 in-corpus citations
Full text JSON View on OpenAlex View at publisher
AI-generated summary by claude@2026-06+body, 2026-06-07

Gestrinone and danazol showed similar efficacy and pregnancy rates in endometriosis treatment, but with differing side effects, while buserelin achieved implant reduction in 80% of patients.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text

This paper compares hormonal therapies for endometriosis using randomized data in 30 laparoscopically proven patients treated for 6 months with gestrinone versus danazol, reporting effective treatment in roughly 80–90% of cases and similar pregnancy rates, alongside different side-effect profiles between groups. It also describes a multinational, multicenter trial of buserelin (GnRH agonist) in 275 patients, where in 80% the treatment led to disappearance or reduction of endometriotic implants, with main side effects attributed to estrogen suppression. A key limitation stated in the summary is the ongoing investigation of different hormonal methods, especially regarding recurrence rates and long-term side effects rather than definitive long-term outcomes. This paper is centrally about endometriosis — it evaluates and summarizes randomized trial outcomes for gestrinone, danazol, and buserelin in treating endometriotic implants and compares their efficacy and side effects.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 4,754 characters · extracted from oa-doi-fallback · click to expand
Summary In a randomized study, the effect of gestrinone (2 × 2,5 mg/week) was compared with the effect of danazol (3 × 200 mg/day) in treating 30 patients with laparoscopically proven endometriotic implants for 6 months. Therapy was effective in 80%–90% of cases and pregnancy rates were similar, but the incidence of side effects was different in the groups. In addition, buserelin (900 µg/day intranasally) was investigated in a multinational, multicenter trial in 275 patients. In 80%, GnRH agonsit treatment induced the disappearance or reduction of endometriotic implants. The main side effects were due to estrogenic suppression. Presently, various methods of hormonal treatment are under investigation, especially to determine recurrency rates of endometriosis and long-term side effects. Zusammenfassung In einer randomisierten Studie wurden bei 30 Patientinnen 6 Monate lang die Wirkungen von Gestrinon (2 × 2,5 mg/Woche) und Danazol (3 × 200 mg/Tag) verglichen. Bei erfolgreicher Therapie in 80–90% der Fälle und ähnlicher Schwangerschaftsrate traten in beiden Gruppen jedoch unterschiedliche Nebenwirkungen auf. Zusätzlich wurde Buserelin in einer multinationalen multizentrischen Studie an 275 Patientinnen mit intranasalen Gaben von 900 µg/Tag untersucht. Bei 80% führte die Behandlung mit dem GnRH-Agonisten zum Abheilen oder zum Rückgang der Implantate. Die hauptsächlichen Nebenwirkungen waren auf die Östrogensuppression zurückzuführen. Zur Zeit werden verschiedene Methoden im Hinblick auf Rezidivraten und Langzeit-Nebenwirkungen getestet. Preview Unable to display preview. Download preview PDF. Similar content being viewed by others Literatur Cirkel U, Schweppe KW, Ochs H, Schneider HPG (1987) Metabolische Effekte und allgemeine Nebenwirkungen bei Endometriosebehandlung mit einem LHRH-Agonisten. Geburtsh Frauenheilk 47: 154–157 Cornillie FJ, Vasquez G, Brosens I (1985) The response of human endometriotic implants to the anti-progesterone steroid R 2323: a histologic and ultrastructural study. Path Res Pract 180: 647–655 Dlugi AM, Rufo S, D’Amico JF, Seibel MM (1988) A comparison of the effects of Buserelin versus danazol on plasma lipoproteins during treatment of pelvic endometriosis. Fertil Steril 49: 913–916 Donnez J, Lemaire-Rubbers M, Karaman Y, Nisolle-Pochet M, Casanas-Roux F (1987) Combined (hormonal and microsurgical) therapy in infertile women with endometriosis. Fertil Steril 48: 239–242 Hardt W, Schmidt-Gollwitzer M, Schmidt-Gollwitzer K, Genz T, Nevinny-Stickel J (1986) Initial results in the treatment of endometriosis with the LH RH analogue buserelin. Geburtsh Frauenheilk 46: 483 Henzl MR, Corson SL, Moghissi K, Buttram VC, Berquist C, Jacobson J (1988) Administration of nasal nafarelin as compared with oral danazol for endometriosis. N Engl J Med 318: 485–489 Kiesel L, Bertges K, Rabe T, Runnebaum B (1986) Gonadotropin releasing hormone enhances polyphosphoinositide hydrolyis in rat pituitary cells. Biochem Biophys Res Commun 134: 861 Kiesel L, Catt KJ (1987) Stimulation of luteinizing hormone release and cyclic nucleotide production by arachidonic acid in cultured gonadotrophs. Neuroendocrinology 46: 1 Kiesel L, Kaufmann M, Haeseler F, Klinga K, von Holst T, Schmidt W, Runnebaum B (1988) GnRH receptors in human breast cancer tissue. Geburtsh Frauenheilk 48: 420–424 Lemay A, Maheux R, Faure N, Jean C, Fazekas ATA (1984) Reversible hypogonadism induced by luteinizing hormone releasing hormone (LHRH) agonist (buserelin) as a new therapeutic approach for endometriosis. Fertil Steril 41: 863 Mettler L (1987) Vergleich der medikamentösen Behandlung der Endometriosis genitalis externa mit Gestrinon, Lynestrenol und Danazol im Rahmen der Drei-Stufen-Behandlung. Fertilität 3: 133–139 Schneider HPG, Schweppe K-W, Cirkel U, Ochs H (1986) Management of endometriosis. In: Rolland R, Chadha DR, Willemsen WNP (eds) Gonadotropin Down-Regulation in Gynecological Practice. Progr Clin Biol Res vol 225. Alan R Liss, New York, pp 135–156 Schweppe K-W (1984) Morphologie und Klinik der Endometriose. Schattauer, Stuttgart New York Author information Authors and Affiliations Editor information Editors and Affiliations Rights and permissions Copyright information © 1989 Springer-Verlag Berlin Heidelberg About this paper Cite this paper Kiesel, L., Bertges, K., Rabe, T., von Holst, T., Runnebaum, B. (1989). Therapie der Endometriose. In: Ludwig, H., Krebs, D. (eds) Gynäkologie und Geburtshilfe 1988. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74784-7_482 Download citation DOI: https://doi.org/10.1007/978-3-642-74784-7_482 Publisher Name: Springer, Berlin, Heidelberg Print ISBN: 978-3-642-74785-4 Online ISBN: 978-3-642-74784-7 eBook Packages: Springer Book Archive

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (12)

Cited by (5)

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK